Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Dis Esophagus ; 29(6): 572-9, 2016 Aug.
Article in English | MEDLINE | ID: mdl-25893629

ABSTRACT

Upper gastrointestinal perforations, fistula, and anastomotic leaks are severe conditions with high mortality. Temporary endoscopic placement of fully covered self-expanding metal stent (fSEMS) has emerged as treatment option. Stent migration is a major drawback of currently used stents. Migration is often attributed to a relatively too small stent diameter as esophageal stents were initially intended for the treatment of strictures. This study aimed to investigate the safety and efficacy of a large-diameter fSEMS for treatment of these conditions. Data were retrospectively collected from patients who received this stent in the Netherlands between March 2011 and August 2013. Clinical success was defined as sufficient leak closure after stent removal as confirmed by endoscopy or X-ray with oral contrast without surgical intervention or placement of another type of stent. Adverse events were graded according a standardized grading system. Stent placement was performed in 34 patients for the following indications: perforation (n = 6), anastomotic leak (n = 26), and fistula (n = 2). Technical success rate was 97% (33/34). Clinical success rate was 44% (15/34) after one stent and 50% (17/34) after an additional stent. There were no severe adverse events and stent-related mortality. The overall adverse event rate was 50% (all graded 'moderate'). There were 14 (41%) stent migrations (complete n = 8, partial n = 6). Other adverse events were bleeding (n = 2) and aspiration pneumonia (n = 1). Reinterventions for failure of the large-diameter fSEMS were placement of another type of fSEMS (n = 4), surgical repair (n = 3), or esophagectomy (n = 1). Eleven patients (32%) died in-hospital because of persisting intrathoracic sepsis (n = 10) or preexistent bowel ischemia (n = 1). This study suggests that temporary placement of a large-diameter fSEMS for the treatment of upper gastrointestinal perforations, fistula, and anastomotic leaks is safe in terms of severe adverse events and stent-related mortality. The larger diameter does not seem to prevent stent migration.


Subject(s)
Anastomotic Leak/surgery , Bariatric Surgery , Esophageal Fistula/surgery , Esophageal Perforation/surgery , Esophagectomy , Esophagoscopy , Postoperative Complications/surgery , Self Expandable Metallic Stents , Aged , Cohort Studies , Female , Humans , Male , Middle Aged , Pneumonia, Aspiration/epidemiology , Postoperative Hemorrhage/epidemiology , Prosthesis Failure , Retrospective Studies , Treatment Outcome
2.
Ned Tijdschr Geneeskd ; 151(25): 1412-7, 2007 Jun 23.
Article in Dutch | MEDLINE | ID: mdl-17668608

ABSTRACT

A 56-year-old man with Henoch Schönlein purpura vasculitis suffered from repeated and multiple life-threatening gastrointestinal haemorrhages. Over recent years a number of interventions for the treatment of gastrointestinal haemorrhaging have become available; choosing which option to use can present difficulties. The available interventions are carried out by different disciplines and include haemostatic drugs, endoscopic intervention, intervention radiology, and surgery. In this patient, following a severe drop in haemoglobin levels, CT and angiography revealed active bleeding in the distal jejunum. Transarterial embolization by means of a coiling procedure halted the bleeding. The patient was also given tranexamic acid, a fibrinolysis inhibitor. More episodes of bleeding subsequently followed which necessitated further coiling procedures, two bowel resections, the endoscopic clipping of a bleeding artery, treatment with the recombinant activated factor VII (rFVIIa) at a dosage of 90 microg/kg, as well as conservative treatment with multiple transfusions of filtered erythrocytes and fresh plasma. The patient eventually recovered.


Subject(s)
Gastrointestinal Hemorrhage/etiology , IgA Vasculitis/complications , Blood Transfusion , Factor VIIa/therapeutic use , Gastrointestinal Hemorrhage/drug therapy , Gastrointestinal Hemorrhage/surgery , Humans , Jejunal Diseases/drug therapy , Jejunal Diseases/etiology , Jejunal Diseases/surgery , Male , Middle Aged , Recombinant Proteins/therapeutic use , Treatment Outcome
3.
Ned Tijdschr Geneeskd ; 151(8): 478-83, 2007 Feb 24.
Article in Dutch | MEDLINE | ID: mdl-17378305

ABSTRACT

A 49-year-old woman presented at the emergency ward in shock with upper gastrointestinal bleeding. Extensive ulceration confirmed by gastroduodenoscopy was suggestive of Zollinger-Ellison syndrome. Further evaluation by fasting gastrin assessment, CT, endosonography with cytological biopsy and somatostatin-receptor scintigraphy confirmed the diagnosis ofgastrinoma. Three enlarged lymph nodes near the pancreatic head were surgically removed; each was found to contain neuroendocrine tumour cells. The patient recovered rapidly after surgery and the gastrin level normalised. Zollinger-Ellison syndrome is uncommon but should be considered as a possible cause of upper gastrointestinal bleeding. Shock is very rarely the first sign ofZollinger-Ellison syndrome. In this case, the use of a proton-pump inhibitor may have masked the disease for years.


Subject(s)
Gastrinoma/diagnosis , Pancreatic Neoplasms/diagnosis , Shock, Hemorrhagic/etiology , Zollinger-Ellison Syndrome/diagnosis , Diagnosis, Differential , Female , Gastrinoma/surgery , Gastrointestinal Hemorrhage/etiology , Humans , Middle Aged , Pancreatic Neoplasms/surgery , Treatment Outcome , Zollinger-Ellison Syndrome/surgery
4.
Bone ; 31(1): 158-64, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12110429

ABSTRACT

Osteogenic protein-1 (OP-1), or bone morphogenetic protein-7, is an osteoinductive morphogen that is involved in embryonic skeletogenesis and in bone repair. In bone defect models without spontaneous healing, local administration of recombinant human OP-1 (rhOP-1) induces complete healing. To investigate the ability of rhOP-1 to accelerate normal physiologic fracture healing, an experimental study was performed. In 40 adult female goats a closed tibial fracture was made, stabilized with an external fixator, and treated as follows: (1) no injection; (2) injection of 1 mg rhOP-1 dissolved in aqueous buffer; (3) injection of collagen matrix; and (4) injection of 1 mg rhOP-1 bound to collagen matrix. The test substances were injected in the fracture gap under fluoroscopic control. At 2 and 4 weeks, fracture healing was evaluated with radiographs, three-dimensional computed tomography (CT), dual-energy X-ray absorptiometry, biomechanical tests, and histology. At 2 weeks, callus diameter, callus volume, and bone mineral content at the fracture site were significantly increased in both rhOP-1 groups compared with the no-injection group. As signs of accelerated callus maturation, bending and torsional stiffness were higher and bony bridging of the fracture gap was observed more often in the group with rhOP-1 dissolved in aqueous buffer than in uninjected fractures. Treatment with rhOP-1 plus collagen matrix did not result in improved biomechanical properties or bony bridging of the fracture gap at 2 weeks. At 4 weeks there were no differences between groups, except for a larger callus volume in the rhOP-1 plus collagen matrix group compared with the control groups. All fractures showed an advanced stage of healing at 4 weeks. In conclusion, the healing of a closed fracture in a goat model can be accelerated by a single local administration of rhOP-1. The use of a carrier material does not seem to be crucial in this application of rhOP-1.


Subject(s)
Bone Morphogenetic Proteins/therapeutic use , Recombinant Proteins/therapeutic use , Tibial Fractures/drug therapy , Transforming Growth Factor beta , Absorptiometry, Photon/methods , Animals , Bone Morphogenetic Protein 7 , Diaphyses/diagnostic imaging , Diaphyses/injuries , Female , Goats , Humans , Tibial Fractures/diagnostic imaging , Tomography, X-Ray Computed/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...